Lamassu Pharma is developing RABI-767, a novel small molecule lipase inhibitor designed to mitigate the systemic toxicity and organ failure associated with severe acute pancreatitis, which leads to significant hospitalization and mortality rates. The therapy aims to expedite the transition from preclinical efficacy to clinical trials, ultimately improving patient outcomes and reducing healthcare costs.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Severe acute pancreatitis is associated with systemic toxicity and organ failure, leading to significant hospitalization and mortality rates. Current treatment options are limited, resulting in ineffective medications, long-term complications, and extended hospital stays.
Solution
Lamassu Pharma is developing RABI-767, a novel small molecule lipase inhibitor, to address the unmet clinical need for acute pancreatitis treatment. RABI-767 is designed to mitigate the systemic toxicity and organ failure associated with severe acute pancreatitis. The therapy has demonstrated profound preclinical efficacy in completely mitigating mortality and morbidity associated with severe acute pancreatitis. Lamassu Pharma focuses on translational research to bring RABI-767 to human trials and partner with clinical and commercial development partners.
Target Audience
The primary target audience includes patients suffering from acute pancreatitis, as well as hospitals and healthcare providers seeking improved treatment options.
Features
- Novel small molecule lipase inhibitor
- Designed to mitigate systemic toxicity and organ failure associated with severe acute pancreatitis
- Demonstrated profound preclinical efficacy in mitigating mortality and morbidity
- Aims to reduce hospitalization rates and improve patient outcomes
- Currently preparing for Phase 1 clinical trials